Navigation Links
PAREXEL Opens New Office in Japan and Further Strengthens Leading Presence in Asia/Pacific Region
Date:10/4/2010

BOSTON, Oct. 4 /PRNewswire/ -- PAREXEL International Corporation (Nasdaq: PRXL), a leading global biopharmaceutical services provider, today announced that the Company has opened a new office in Nagoya, Japan to support a growing demand for a broad range of clinical development and regulatory consulting capabilities in the country and throughout the Asia/Pacific region. This office further expands PAREXEL's presence in Japan, which includes locations in Tokyo and Kobe. PAREXEL now has 18 offices throughout important biopharmaceutical centers in the Asia/Pacific region, which in addition to Japan also includes a strong presence in Australia, China, India, Indonesia, Malaysia, the Philippines, Singapore, South Korea, Taiwan, and Thailand.

"Japan continues to maintain its position as the second largest pharmaceutical market globally, and is among the most mature markets within the Asia/Pacific region. Japan is attractive to our worldwide client base for inclusion in global studies not only for its market potential but also for its high quality data, advanced technologies, and large pool of well-trained professionals. Clients have continued to rely on PAREXEL's in-depth expertise in Japan as well as our fully-integrated, harmonized global processes and standards to support their programs," said Josef von Rickenbach, Chairman and Chief Executive Officer, PAREXEL International.

"The opening of our office in Nagoya builds on our established presence and long-term, ongoing commitment to Japan. PAREXEL's expansion in Japan allows us to further assist locally-based clients with regional and global market access opportunities. Our regulatory and clinical experts are supporting what we call 'Japan plus Asia' studies since recent regulatory changes allow for inclusion of non-Japanese data for registration purposes. We are also su
'/>"/>

SOURCE PAREXEL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. PAREXEL Expands Late Phase Clinical Research Services and Appoints Leading Pharmacoepidemiology Expert Victor Kiri
2. PAREXEL Expands Global Clinical Pharmacology Capabilities
3. PAREXEL Data Reveal A Record High Number of Clinical Trials Initiated
4. PAREXEL Strengthens Leading Presence in Latin America With a New Location in Peru
5. PAREXEL Reaches Milestone in Management of Oncology Trials Over Last Five Years Involving 175,000 Patients Worldwide
6. PAREXEL International to Present at William Blair Emerging Growth Stock Conference
7. PAREXEL Reports First Quarter Fiscal Year 2010 Financial Results
8. PAREXEL Enhances Early Phase Cardiac Safety Capabilities Through Alliance With Mortara Instrument
9. PAREXEL Expert To Lead Panel on Innovative Drug Development in Asia at Partnerships in Clinical Trials Asia Pacific Conference
10. PAREXEL Introduces Temperature Recording Solution for Study Drug Transportation, Bringing More Efficiency to Clinical Supply Chain
11. PAREXEL Announces Strategic Functional Service Provider Relationship with Eli Lilly and Company for Clinical Development in Asia/Pacific Region
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... , Sept. 2, 2014  XBiotech announced ... study being conducted in the US for its ... Human™ monoclonal antibody therapy, is being evaluated in ... complicated with cachexia. The primary endpoint of the ... treated patients to a control population provided only ...
(Date:9/2/2014)...   Santa Clara dentist , Dr. Alan ... Invisalign. Invisalign is an orthodontic system that uses clear ... the orthodontic treatment of choice for older teens and ... For a limited time, patients can try Invisalign for ... usual cost. This offer cannot be combined, and some ...
(Date:9/2/2014)... , September 2, 2014 ... CONGRESS 2014 provide insight into treatment and outcomes ... clinical practice --   Data from ... Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, ... prevention strategies for atrial fibrillation (AF) patients remain ...
Breaking Medicine Technology:XBiotech Halts Study, Reports Positive Phase III Results with Antibody Therapy for Cancer 2Santa Clara Cosmetic Dentist, Dr. Alan Frame, is Now Offering a Special on Invisalign 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 2Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 3Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 4Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 5Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 6Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 7Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 8Data From Global Atrial Fibrillation Registry Show Antithrombotic Agents Not Optimally Used to Prevent Stroke 9
... CANTEL MEDICAL CORP. (NYSE: CMN ) ... per diluted share, on a 24% increase in sales to a ... compares with net income of $4,274,000, or $0.25 per diluted share, ... 2010.  For the nine months ended April 30, 2011, the Company ...
... Pa., June 8, 2011 TetraLogic Pharmaceuticals, a biopharmaceutical ... treat cancer, today announced the appointment of Mr. Jonathan ... and vice president of corporate development. ... of corporate development and finance experience.  He has led ...
Cached Medicine Technology:Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 2Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 3Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 4Cantel Medical Reports 18% Increase in Net Income on 24% Increase in Sales 5TetraLogic Appoints Jonathan B. Lloyd Jones as Chief Financial Officer and Vice President Corporate Development 2
(Date:9/2/2014)... New York, New York (PRWEB) September 02, 2014 ... metal-on-metal version of the DePuy Pinnacle hip implant ... jury selection begins today in the U.S. District ... reports. According to court documents, Johnson & Johnson ... 6,000 lawsuits that allege the all-metal hip caused ...
(Date:9/2/2014)... Raton, FL (PRWEB) September 02, 2014 ... audience targeting and multi-channel email marketing is pleased to ... the market, Firearms & Freedom as well ... online properties represent more than one million concerned Americans ... display advertising. , “We are honored to continue ...
(Date:9/2/2014)... research shows a novel polypill increases patient adherence ... heart attack, according to new study results reported ... 2014 in Barcelona, Spain. According to Principal Investigator ... Heart at Icahn School of Medicine at Mount ... de Investigaciones Cardiovasculares Carlos III (CNIC) in Madrid, ...
(Date:9/2/2014)... San Diego School of Medicine have identified an enzyme ... findings, reported in the current issue of PNAS, offer ... worldwide. An estimated 40,000 women in America will die ... Cancer Society. , "The take-home message of the study ... breast cancer metastasis through a pathway regulated by an ...
(Date:9/2/2014)... associated with many health risks, including heart disease and ... possible way to mitigate one often-overlooked risk: not buckling ... by Sheldon H. Jacobson, a professor of computer science ... are associated with a decrease in seatbelt usage. However, ... in effect. , "Primary seatbelt laws lead to increased ...
Breaking Medicine News(10 mins):Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 2Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 3Health News:DePuy Pinnacle Lawsuit Set For Trial in Federal Litigation, as Jury Selection Begins Today, Bernstein Liebhard LLP Reports 4Health News:ASG Continues to Bring New Lists to Market 2Health News:ASG Continues to Bring New Lists to Market 3Health News:New polypill increases heart attack patients' medication adherence 2Health News:New polypill increases heart attack patients' medication adherence 3Health News:Enzyme controlling metastasis of breast cancer identified 2Health News:Seatbelt laws encourage obese drivers to buckle up 2
... taken the National Polio Eradication Initiatives and now in ... Days (NIDs) have planned to immunize 22 million children ... ,Government of Bangladesh will carry out the initiatives ... (WHO), Rotary International and the U.S. Centers for Disease ...
... announced that, a novel treatment for brain tumors has ... as 'Oncophage' treatment, is aimed at tackling an aggressive ... of California, are at the helm of this research. ... from a portion of a patient's tumor. After breaking ...
... at least five times a year have more health problems ... ,And people with a severe gambling addiction are ... increased heart rate, angina and liver disease when compared to ... ,“One of the questions that has never been answered is ...
... women put on as they age, according to a finding ... doctor.//,In a study that followed more than 68,000 US women ... of Case Western Reserve University in Cleveland found that women ... weight during middle age. ,The findings were published in ...
... to the remedy of choice to treat chronic constipation.//A ... claims that, it is far more superior in effectiveness ... chronic constipation do not seem to offer the same ... disorder, affecting the intestinal tract .Today, its estimated that ...
... has found anti-clotting drug called bivalirudin (Angiomax) that beats ... coronary syndromes such as heart// attacks. This new blood ... from acute coronary syndromes. ,The Results of ... trial’ were published in November issue of the New ...
Cached Medicine News:Health News:Odds Are That Gamblers Have More Health Problems 2Health News:New Anti-Clotting Drug Less Risky For Heart Attack Patients 2
Livewire TC steerable ablation catheters are designed for the RF ablation of arrhythmias. They are available in a variety of curves and configurations, including bi-directional catheters for added fl...
Trilogy Pacemakers incorporates the clinically proven Omniscence™ accelerometer sensor with it's automatic alogorithms. The Trilogy family of pacemakers feature an array of products for bradyar...
... The Integrity ADx ... the world's smallest dual-chamber ... advanced pacemaker technology, including ... algorithm, the first U.S. ...
... Frontier II device is designed ... moderate to severe heart failure ... in patients who are symptomatic ... and who have prolonged QRS ...
Medicine Products: